Planet 13 Holdings (PLNH) Change in Accured Expenses (2022 - 2026)
Planet 13 Holdings' (PLNH) quarterly Change in Accured Expenses came in at -$1.4 million in Q1 2026, down 1682.93% year-on-year from $86673.0 in Q1 2025, and down 237.01% on a QoQ basis from -$407100.0 in Q3 2025.
Planet 13 Holdings (PLNH) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 5 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 1682.93% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 27.75% increase from a year earlier, with the FY2024 full-year figure at -$2.9 million, down 50.95% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.4 million, down from -$407100.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for PLNH reached as high as $1.9 million in Q4 2022 and fell as low as -$3.7 million in Q4 2024.
- Historically, Change in Accured Expenses has averaged -$347332.9 across 5 years, with a median of -$300374.5 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 194.14% in 2024 and fell as far as 1796.43% in 2024.
- Year by year, Change in Accured Expenses stood at $1.9 million in 2022, then sank by 110.0% to -$193649.0 in 2023, then tumbled by 1796.43% to -$3.7 million in 2024, then surged by 88.91% to -$407100.0 in 2025, then slumped by 237.01% to -$1.4 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.4 million in Q1 2026, -$407100.0 in Q3 2025, and $318755.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Planet 13 Holdings | 39.32 Mn | 23.06 Mn | 9.41 Mn | -1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Sep 30, 2025 | -407,100.00 |
| Sep 30, 2025 | -407,100.00 |
| Jun 30, 2025 | 318,755.00 |
| Jun 30, 2025 | 318,755.00 |
| Mar 31, 2025 | 86,673.00 |
| Mar 31, 2025 | 86,673.00 |
| Dec 31, 2024 | -3.67 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | 632,052.00 |
| Sep 30, 2024 | 632,052.00 |
| Jun 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | -956,061.00 |
| Mar 31, 2024 | -956,061.00 |
| Dec 31, 2023 | -193,649.00 |
| Dec 31, 2023 | -193,649.00 |
| Sep 30, 2023 | -671,400.00 |
| Sep 30, 2023 | -671,400.00 |